In vitro biological responses of plasma nanocoatings for coronary stent applications.

Phan, ThiThuHa; Jones, John E; Chen, Meng; Strawn, T L; Khoukaz, Hekmat B; Ji, Yan; Kumar, Arun; Bowles, Douglas K et al. · J Biomed Mater Res A · 2023

basic_science · Level V

Where this comes from

Abstract

In-stent restenosis and thrombosis remain to be long-term challenges in coronary stenting procedures. The objective of this study was to evaluate the in vitro biological responses of trimethylsilane (TMS) plasma nanocoatings modified with NH<sub>3</sub> /O<sub>2</sub> (2:1 molar ratio) plasma post-treatment (TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoatings) on cobalt chromium (CoCr) alloy L605 coupons, L605 stents, and 316L stainless steel (SS) stents. Surface properties of the plasma nanocoatings with up to 2-year aging time were characterized by wettability assessment and x-ray photoelectron spectroscopy (XPS). It was found that TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoatings had a surface composition of 41.21 ± 1.06 at% oxygen, 31.90 ± 1.08 at% silicon, and 24.12 ± 1.7 at% carbon, and very small but essential amount of 2.77 ± 0.18 at% nitrogen. Surface chemical stability of the plasma coatings was noted with persistent O/Si atomic ratio of 1.292-1.413 and N/Si atomic ratio of ~0.087 through 2 years. The in vitro biological responses of plasma nanocoatings were studied by evaluating the cell proliferation and migration of porcine coronary artery endothelial cells (PCAECs) and smooth muscle cells (PCASMCs). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay results revealed that, after 7-day incubation, TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoatings maintained a similar level of PCAEC proliferation while showing a decrease in the viability of PCASMCs by 73 ± 19% as compared with uncoated L605 surfaces. Cell co-culture of PCAECs and PCASMCs results showed that, the cell ratio of PCAEC/PCASMC on TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoating surfaces was 1.5-fold higher than that on uncoated L605 surfaces, indicating enhanced selectivity for promoting PCAEC growth. Migration test showed comparable PCAEC migration distance for uncoated L605 and TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoatings. In contrast, PCASMC migration distance was reduced nearly 8.5-fold on TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoating surfaces as compared to the uncoated L605 surfaces. Platelet adhesion test using porcine whole blood showed lower adhered platelets distribution (by 70 ± 16%), reduced clotting attachment (by 54 ± 12%), and less platelet activation on TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoating surfaces as compared with the uncoated L605 controls. It was further found that, under shear stress conditions of simulated blood flow, TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoating significantly inhibited platelet adhesion compared to the uncoated 316L SS stents and TMS nanocoated 316L SS stents. These results indicate that TMS + NH<sub>3</sub> /O<sub>2</sub> nanocoatings are very promising in preventing both restenosis and thrombosis for coronary stent applications.

Medical subject headings